Circassia BOlsters Drug Portfolio
Circassia Ltd., an Oxford, England-based drug company focused on controlling immune system responses, has acquired the U.S., Canadian and Japanese development and commercialization rights to dopexamine from Ipsen. No financial terms were disclosed. Circassia has raised around $22 million in VC funding from firms like Goldman Sachs, Invesco Perpetual, Imperial Innovations and Lansdowne Partners.
8 October 2008•3 mins read
